older antipsychotics offer once-daily dosing or even less frequent dosing schedules. After initially projecting Cobenfy could achieve $5.5 billion in revenue in 2030, Leerink has slashed that ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol Myers Squibb BMY was down on data from the schizophrenia study while ...

Treatment with Cobenfy as an adjunctive demonstrated a ... seeking addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved ...

Cobenfy is also in phase 3 clinical testing ... currently in two phase 2 studies. It offers once-daily dosing, versus twice-daily with BMS' drug and, according to some assessments, could be ...

No signs of tolerance were seen after sub-chromic dosing and more than 30-fold safety ... perhaps most notably the failure of the Phase 3 trial of COBENFY as adjunctive treatment in schizophrenia?

3) Bristol Myers Squibb's Cobenfy (KarXT; xanomeline and trospium ... 13 antibody for atopic dermatitis that offers less frequent dosing than its two predecessors in the class, Sanofi/Regeneron's ...

Cobenfy (xanomeline/trospium) is a prescription drug used to treat schizophrenia. Cobenfy comes as an oral capsule. Cobenfy is used in adults to treat schizophrenia. To learn more about Cobenfy ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year.

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that ...